BidaskClub Upgrades Catalyst Pharmaceuticals (CPRX) to “Sell”

Catalyst Pharmaceuticals (NASDAQ:CPRX) was upgraded by investment analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a research report issued on Wednesday.

Other analysts also recently issued research reports about the stock. HC Wainwright reissued a “buy” rating and set a $6.00 target price on shares of Catalyst Pharmaceuticals in a research report on Thursday, March 15th. ValuEngine raised shares of Catalyst Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Monday. Two research analysts have rated the stock with a sell rating and five have issued a buy rating to the company. Catalyst Pharmaceuticals presently has an average rating of “Hold” and a consensus price target of $6.25.

Shares of NASDAQ CPRX opened at $3.34 on Wednesday. Catalyst Pharmaceuticals has a 1 year low of $3.33 and a 1 year high of $3.46.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last issued its quarterly earnings data on Wednesday, May 9th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.06). equities analysts expect that Catalyst Pharmaceuticals will post -0.34 EPS for the current fiscal year.

In other news, insider Patrick J. Mcenany bought 20,000 shares of the firm’s stock in a transaction on Tuesday, April 3rd. The stock was acquired at an average price of $2.29 per share, with a total value of $45,800.00. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 9.60% of the company’s stock.

Several hedge funds have recently made changes to their positions in CPRX. Consonance Capital Management LP grew its position in shares of Catalyst Pharmaceuticals by 1,111.4% during the 4th quarter. Consonance Capital Management LP now owns 4,473,607 shares of the biopharmaceutical company’s stock worth $17,492,000 after buying an additional 4,104,309 shares during the period. Millennium Management LLC acquired a new stake in shares of Catalyst Pharmaceuticals during the 4th quarter worth approximately $8,082,000. Emerald Advisers Inc. PA acquired a new stake in shares of Catalyst Pharmaceuticals during the 4th quarter worth approximately $5,364,000. Driehaus Capital Management LLC acquired a new stake in shares of Catalyst Pharmaceuticals during the 4th quarter worth approximately $4,812,000. Finally, EAM Investors LLC acquired a new stake in shares of Catalyst Pharmaceuticals during the 4th quarter worth approximately $4,076,000. 55.30% of the stock is owned by institutional investors.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company. It focuses on development and commercialization of prescription drugs targeting rare (orphan) neuromuscular and neurological diseases, including Lambert-Eaton Myasthenic Syndrome (LEMS), infantile spasms, and Tourette’s disorder. The company was founded by McEnany J.

Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply